Biologics for asthma and risk of pneumonia.
Maria Gabriella MateraJosuel OraLuigino CalzettaPaola RoglianiMario CazzolaPublished in: The Journal of asthma : official journal of the Association for the Care of Asthma (2024)
Mepolizumab, omalizumab and benralizumab, but not dupilumab, were associated with high odds of reporting pneumonia. Our results represent only potential associations between these biologics and pneumonia but not causality. The nature of the FAERS database is such that the cause of the reported events is uncertain. Therefore, we can only roughly estimate the incidence of AEs by the signal strength (ROR value). Nevertheless, although causality could not be assessed, the signal from our study is interesting. We believe it deserves to be further substantiated by real-world studies with robust designs.